HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opi Products

This article was originally published in The Rose Sheet

Executive Summary

Opi Lip Liner, available in December at salons nationwide, "utilizes the same technology as Opi Lip Colour to provide not only a smear and fade resistant finish, but maximum coverage" as well, the firm states. One-page ads with the tagline "From your lips, to our ears" will appear in January trade publications such as Modern Salon, American Salon, Nails and Nail Pro. The liner is available in 33 shades, such as Cajun Shrimp, Taos Twist and Lillehammer Lingonberry, that coordinate with Opi Lip Colour and Nail Lacquer colors. The liners retail for $10 each. Opi also sells a wide range of hand and nail care products including Avoplex Natural Nail and Cuticle Treatment, Avoplex Hand Care Lotion, RapiDry Nail Polish Dryer, Swiss Blue Liquid Hand Soap and N-A-S '99' Nail Cleanser, all of which sold at retail in salons only

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel